Reporting to the Head of CI & RPM, this role proactively identifies, evaluates, and shapes external opportunities across PROTACs, molecular glues, monovalent/direct degraders, degrader platforms, E3/UPS biology including CRBN, VHL, and novel E3 ligases, target engagement, proteomics/chemoproteomics, structural and computational degrader design, Degrader Antibody Conjugates (DACs), next-generation induced-proximity technologies such as RIPTAC and TCIP, and other oncology-relevant targeted-delivery or induced-proximity modalities. + Actively track scientific and company activity across PROTACs, molecular glues, monovalent/direct degraders, novel E3 ligase recruiters, CRBN/VHL biology, target engagement, proteomics/chemoproteomics, next-generation induced-proximity technologies such as RIPTAC and TCIP, and DACs.